Patients With Cancer
Recently Published Documents





2021 ◽  
Suzanne Festen

JAMA Oncology ◽  
2021 ◽  
Pierre-Marie Morice ◽  
Basile Chrétien ◽  
Angélique Da Silva ◽  
Charles Dolladille ◽  
Joachim Alexandre

2021 ◽  
Vol 193 (40) ◽  
pp. E1551-E1560
Miriam Kimpton ◽  
Srishti Kumar ◽  
Philip S. Wells ◽  
Doug Coyle ◽  
Marc Carrier ◽  

2021 ◽  
Vol 8 ◽  
Qi Zhang ◽  
Liang Qian ◽  
Tong Liu ◽  
Jia-Shan Ding ◽  
Xi Zhang ◽  

Background: Malnutrition is common in patients with cancer and is associated with adverse outcomes, but few data exist in elderly patients. The aim of this study was to report the prevalence of malnutrition using three different scoring systems and to examine the possible clinical relationship and prognostic consequence of malnutrition in elderly patients with cancer.Methods: Nutritional status was assessed by using controlling nutritional status (CONUT), the prognostic nutritional index (PNI), and the nutritional risk index (NRI). Quality-of-life (Qol) was assessed during admission by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30. Performance status (PS) was assessed by using the Eastern Cooperative Oncology Group (ECOG) classification. The relationship between nutritional status and overall survival and Qol were examined.Results: Data were available for 1,494 elderly patients with cancer (63.65% male), the mean age was 70.76 years. According to the CONUT, NRI, and PNI, 55.02, 58.70, and 11.65% patients were diagnosed with malnutrition, respectively. Worse nutritional status was related to older, lower BMI, lower hand grip strength, and more advanced tumor stage. All malnutrition indexes were correlated with each other (CONUT vs. PNI, r = −0.657; CONUT vs. NRI scores, r = −0.672; PNI vs. NRI scores, r = 0.716, all P < 0.001). During a median follow-up of 43.1 months, 692 (46.32%) patients died. For patients malnourished, the incidence rate (events-per-1,000person-years) was as follows: CONUT (254.18), PNI (429.91), and NRI (261.87). Malnutrition was associated with increased risk for all-cause mortality (adjust HR [95%CI] for CONUT: 1.09 [1.05–1.13], P < 0.001; PNI: 0.98[0.97–0.99], P < 0.001; NRI: 0.98 [0.98–0.99], P < 0.001). All malnutrition indexes improved the predictive ability of the TNM classification system for all-cause mortality. Deterioration of nutritional status was associated with deterioration in Qol parameters and immunotherapeutic response (P < 0.001).Conclusions: Malnutrition was prevalent in elderly patients with cancer, regardless of the assessment tools used, and associated with lower Qol and the immunotherapy response.

Cancer ◽  
2021 ◽  
Kate E. Lee ◽  
David A. Bender ◽  
Lawrence D. Koutcher ◽  
Brigham Hyde ◽  
Chin Hur ◽  

2021 ◽  
Vol 3 (4) ◽  

Biomedicines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1389
Ana Rita da Silva Ferreira ◽  
Anne-Grete Märtson ◽  
Alyse de Boer ◽  
Hannah R. Wardill ◽  
Jan-Willem Alffenaar ◽  

Antimicrobial prophylaxis is increasingly being used in patients with hematological malignancies receiving high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). However, few studies have focused on the potential impact of gastrointestinal mucositis (GI-M), a frequently observed side effect of chemotherapy in patients with cancer that affects the gastrointestinal microenvironment, on drug absorption. In this review, we discuss how chemotherapy leads to an overall loss of mucosal surface area and consequently to uncontrolled transport across the barrier. The barrier function is depending on intestinal luminal pH, intestinal motility, and diet. Another factor contributing to drug absorption is the gut microbiota, as it modulates the bioavailability of orally administrated drugs by altering the gastrointestinal properties. To better understand the complex interplay of factors in GI-M and drug absorption we suggest: (i) the longitudinal characterization of the impact of GI-M severity on drug exposure in patients, (ii) the development of tools to predict drug absorption, and (iii) strategies that allow the support of the gut microbiota. These studies will provide relevant data to better design strategies to reduce the severity and impact of GI-M in patients with cancer.

Matthew F. Hudson ◽  
Scott A. Strassels ◽  
Danielle D. Durham ◽  
Sunny Siddique ◽  
David Adler ◽  

Sign in / Sign up

Export Citation Format

Share Document